Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a tetraspanin transmembrane protein predominantly expressed on normal and malignant B cells. This phase I, open-label study used a modified 3 + 3 design to evaluate the safety, maximum tolerated dose (MTD), pharmacokinetics, and prel...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Invest New Drugs
Päätekijät: Kroschinsky, Frank, Middeke, Jan Moritz, Janz, Martin, Lenz, Georg, Witzens-Harig, Mathias, Bouabdallah, Reda, La Rosée, Paul, Viardot, Andreas, Salles, Gilles, Kim, Seok Jin, Kim, Tae Min, Ottmann, Oliver, Chromik, Joerg, Quinson, Anne-Marie, von Wangenheim, Ute, Burkard, Ute, Berk, Andreas, Schmitz, Norbert
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2020
Aiheet:
Phase I Studies
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497676/
https://ncbi.nlm.nih.gov/pubmed/32172489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00916-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia